Life Sciences. GxP-grade evidence for software, AI, and the supply chain underneath.
Pharma, biotech, and clinical research organisations run on validated systems and trial-grade data. 21 CFR Part 11, GAMP 5, ICH E6(R3), and the emerging AI-in-trials guidance turn every CI build and every model deployment into a regulator-visible artefact. Safeguard makes that artefact a signed pipeline output — not a year-long validation exercise.
Four forces converging on every trial submission.
E-signature, data integrity, AI-in-trials, and CRO oversight — all hitting one validated pipeline.
21 CFR Part 11 electronic signatures
FDA expects electronic records and e-signatures with full traceability — who, what, when, why, and the audit trail behind it. Software that touches trial data inherits the same obligation as the records themselves.
Clinical-trial data integrity (ALCOA+)
Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available. Any software in the trial data path has to demonstrably preserve those properties.
EMA / PMDA AI-in-trials guidance
Draft guidance from the EMA and PMDA on AI in clinical research is converging fast. Lineage, validation, drift, and explainability are no longer optional — they have to be in the submission.
Vendor due diligence across CROs
Sponsors run trials through a layered CRO ecosystem. Due diligence cannot stop at the prime contractor; sub-tier vendors carry the same trial data and the same regulator-visible risk.
Capability mapped to inspection-ready expectation.
GxP-validated SBOM pipeline
SBOM emission, signing, retention, and querying run inside a GxP-validated CI pipeline. The pipeline itself ships with IQ / OQ / PQ evidence and a validation summary suitable for inspection.
Clinical-AI model lineage attestation
Every AI model used in the trial workflow carries a signed lineage record — training data scope, training run hash, validation results, deployed version. Available to the regulator as an attestation, not a slide.
Cross-CRO vendor risk
Continuous monitoring across prime CROs and their sub-tier vendors. Concentration risk, residency posture, and breach signals are visible at the sponsor level — not just at quarterly review meetings.
AI-BOM for trial submissions
IND / NDA / MAA submissions increasingly require an AI bill of materials. Safeguard generates the AI-BOM from the same pipeline that emits the software SBOM — one source of truth, machine-readable.
Frameworks the platform is mapped to.
Pre-mapped control narratives and evidence in the formats inspectors at CDER, CBER, EMA, and PMDA already accept.
A typical deployment across sponsor and CRO sites.
GxP-validated CI pipeline, signed trial-AI provenance, multi-site evidence sync, and a CDER / CBER-ready trust packet.
GxP-validated CI pipeline
CI / CD agents, signing infrastructure, and SBOM emission run inside a validated environment. Change control, IQ / OQ / PQ, and validation summary live with the pipeline.
Signed trial-AI provenance
Trial AI models — eligibility, adjudication, safety signal — carry signed lineage from training run to deployed version. SHA-pinned weights, signed model cards.
Multi-site evidence sync
Sponsor sites and CROs across US, EU, and APAC share a common evidence store with per-region residency. Inspection-ready from any site, no email roundtrips.
CDER / CBER-ready trust packet
Pre-mapped submission packet for FDA CDER / CBER, EMA, and PMDA. SBOM, AI-BOM, VEX, audit trail, and validation summary — exported in the formats the reviewer already accepts.
Four risk surfaces every quality and security lead tracks.
Clinical-trial AI model drift
Eligibility, adjudication, and safety-signal models drift quietly as data distributions move. Drift inside a trial is a data-integrity event, not a software bug — and the inspector will treat it that way.
CRO vendor compromise
Prime CROs and sub-tier vendors hold trial data, eCRF systems, and randomisation services. A breach upstream becomes the sponsor's reportable incident and the sponsor's clock.
IND / NDA submission AI lineage gaps
Submissions that reference AI-assisted analysis need a complete lineage record. A gap in lineage becomes an information request from the reviewer — and a delay to the program.
Lab-equipment firmware vulnerabilities
Sequencers, chromatography systems, and bench instruments run software that nobody patches between calibrations. The connected-lab surface is now part of the GxP perimeter.
What is actually hitting life sciences this year.
- Ransomware targeting pharma R&D networksR&D and trial-operations networks are now coordinated targets. Reachability-aware prioritisation turns thousands of generic CVEs into the short list that actually threatens the program.We address this through Eagle reachability + KEV prioritisation
- CRO data leakage eventsSub-tier CRO breaches cascade into sponsor inboxes — and into regulator filings. Continuous TPRM with concentration-risk visibility surfaces the exposure before the notification clock starts.We address this through TPRM with concentration risk heatmap
- AI-trial model poisoningAdversarial inputs and training-data tampering quietly degrade trial AI. Signed lineage and runtime drift detection make poisoning a visible event, not a missing dataset.We address this through AI-BOM + runtime model integrity
- Vendor SBOM gaps in IND submissionsInspectors are reading submission SBOMs and asking for the missing components. A signed, complete SBOM pipeline closes those gaps before the submission lands.We address this through Signed SBOM + attestation
- 21 CFR Part 11 e-signature driftQuiet changes to e-signature flows and audit-trail capture create inspection-finding risk. Continuous control evaluation replaces the annual self-audit.We address this through Compliance evidence pipeline
Quantified benefits for life sciences.
Numbers from production deployments inside sponsors and CROs. Same inspector, same trial, dramatically less submission overhead.
| Metric | Before Safeguard | With Safeguard |
|---|---|---|
| 21 CFR Part 11 evidence prep | 8 weeks | 4 hours |
| Trial-AI lineage attestation prep | 3 weeks | 30 minutes |
| CRO continuous risk monitoring | 0% | 100% |
| Tool consolidation | 6 vendors | 1 |
| Submission AI-BOM prep | 2 weeks | 1 hour |
| Alert noise reduction | 75% | 5% |
| Vendor questionnaire turn-around | 14 days | 4 hours |
Submission-ready evidence, trial-grade integrity.
Talk to the team about GxP-validated SBOM pipelines, AI-BOM for submissions, and a CRO oversight posture that holds up under inspection.